OTCM
IRLAF
Market cap31mUSD
Oct 05, Last price
0.10USD
Name
IRLAB Therapeutics AB
Chart & performance
P/E
—
P/S
2.56
EPS
—
Vol. 1Y
—
Shs. 5Y
7.04%
Rev. 5Y
186.06%
Div Yld LY
—
Div Yld TTM
—
Revenues
57m
-39.28%
Net income
-110m
L+32.34%
CFO
-55m
L-15.81%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
IRLAB Therapeutics AB (publ) is a pharmaceutical company committed to developing treatments for Parkinson's disease. Its clinical pipeline features Mesdopetam, currently progressing through phase IIb/III studies to address dyskinesia, and Pirepemat, which is undergoing phase IIb clinical trials for the management of postural dysfunction. In the preclinical phase, IRLAB is advancing research programs like IRL942 and 1009, aimed at neurodegenerative conditions and the aging process, as well as IRL757, designed to alleviate apathy in various neurological disorders. Additionally, the company is conducting a research project, P003, focused on creating new therapies for individuals with a recent Parkinson's disease diagnosis. IRLAB Therapeutics AB (publ) was founded in 2013 and has its headquarters in Gothenburg, Sweden.
Key people
Independent Chairman of the Board · since 2023
Kristina Torfgard
Chief Executive Officer · since 2024
Nicholas Waters
Executive Vice President, Head - Research and Development · since 2022
Peder Svensson
Director - Computational Chemistry and Biology, Chief Information Officer · since 2016
Clas Sonesson
Chief Scientific Officer · since 2016
Susanna Holm Waters
Director - Biology and Biostatistics · since 2016
Maria Jalmelid
Chief - Clinical Operations · since 2019
Joakim Tedroff
Chief Medical Officer · since 2016
Cecilia Tivert Stenberg
Head - Finance, Human Resources Manager · since 2020
Gunnar Olsson
Director · since 2024
Lars Adlersson
Independent Director · since 2017
Rein Piir
Independent Director · since 2016
Lena Torlegard
Independent Director · since 2018
Headquarters & legal address
Arvid Wallgrens backe 20
Göteborg, O 413 46
SE
Göteborg, O 413 46
SE
Address
Arvid Wallgrens backe 20
Goteborg, O 413 46
SE
Goteborg, O 413 46
SE
Previous name
Grundbulten 6610 AB
Previous name
Integrative Invest AB
Previous name
Integrative Research Laboratories Holding AB
Valuation
Title SEK in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||